Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 237 (TMEM237) is a tetraspanin transmembrane protein that localizes to the ciliary transition zone (TZ), a key compartment at the base of primary cilia in eukaryotic cells[2][3][4][5]. TMEM237 is essential for the formation and maintenance of primary cilia, acting as part of a conserved module of transition zone proteins that regulate the structure and signaling capacity of this organelle[2][4]. Defects or mutations in TMEM237 cause Joubert syndrome 14 (JBTS14) and are implicated in other Joubert syndrome–related disorders due to disrupted ciliogenesis and deregulation of the Wnt signaling pathway[2][3][4]. TMEM237 also interacts with the intestinal riboflavin transporter RFVT-3, influencing the absorption and stability of vitamin B2 in intestinal epithelial cells, and its expression responds to inflammation and nutrient signaling[1][2]. TMEM237 is not a classical receptor, drug target, or enzyme; instead, it is a structural and regulatory ciliary protein with no currently identified direct drug interactions or use as a biomarker or therapeutic target for disease treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 237 (TMEM237).